Journal Article

Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival

Liu, Jie, Huang, Shengyuan, Wang, Dong, Zhou, Yu, Li, Tongxin, Chen, Jianrong, He, Ping, Fu, Yong

2024

Overview

Background To comprehensively elucidate the genomic and mutational features of lung cancer cases, and lung adenocarcinoma (LUAD), it is imperative to conduct ongoing investigations into the genomic landscape. In this study, we aim to analyze the somatic mutation profile and assessed the significance of these informative genes utilizing a retrospective LUAD cohort. Methods A total of 247 Chinese samples were analyzed to exhibit the tumor somatic genomic alterations in patients with LUAD. The Cox regression analysis was employed to identify prognosis‐related genes and establish a predictive model for stratifying patients with LUAD. Results In the Dianjiang People's Hospital (DPH) cohort, the top five frequent mutated genes were (Epidermal growth factor receptor) EGFR (68%), TP53 (30%), RBM10 (13%), LRP1B (9%), and KRAS (9%). Of which, EGFR is a mostly altered driver gene, and most mutation sites are located in tyrosine kinase regions. Oncogene pathway alteration and mutation signature analysis demonstrated the RTK‐RAS pathway alteration, and smoking was the main carcinogenic factor of the DPH cohort. Furthermore, we identified 34 driver genes in the DPH cohort, including EGFR (68%), TP53 (30.4%), RBM10 (12.6%), KRAS (8.5%), LRP1B (8.5%), and so on, and 45 Clinical Characteristic‐Related Genes (CCRGs) were found to closely related to the clinical high‐risk factors. We developed a Multiple Parameter Gene Mutation (MPGM) risk model by integrating critical genes and oncogenic pathway alterations in LUAD patients from the DPH cohort. Based on publicly available LUAD datasets, we identified five genes, including BRCA2, Anaplastic lymphoma kinase (ALK), BRAF, EGFR, and Platelet‐Derived Growth Factor Receptor Alpha (PDGFRA), according to the multivariable Cox regression analysis. The MPGM‐low group showed significantly better overall survival (OS) compared to the MPGM‐high group (p < 0.0001, area under the curve (AUC) = 0.754). The robust performance was validated in 55 LUAD patients from the DPH cohort and another LUAD dataset. Immune characteristics analysis revealed a higher proportion of primarily DCs and mononuclear cells in the MPGM‐low risk group, while the MPGM‐high risk group showed lower immune cells and higher tumor cell infiltration. Conclusion This study provides a comprehensive genomic landscape of Chinese LUAD patients and develops an MPGM risk model for LUAD prognosis stratification. Further follow‐up will be performed for the patients in the DPH cohort consistently to explore the resistance and prognosis genetic features.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Adenocarcinoma / Adenocarcinoma of Lung - genetics / Adenocarcinoma of Lung - mortality / Adenocarcinoma of Lung - pathology / Adult / Aged / Biomarkers, Tumor - genetics / BRCA2 protein / Cancer therapies / China - epidemiology / clinical characteristic‐related genes / Clinical outcomes / Clinical Relevance / East Asian People / Epidermal growth factor receptors / ErbB Receptors - genetics / Family medical history / Female / Genes / Genomes / Genomics / Humans / Immunotherapy / K-Ras protein / Kinases / Leukocytes (mononuclear) / lung adenocarcinoma / Lung cancer / Lung Neoplasms - genetics / Lung Neoplasms - mortality / Lung Neoplasms - pathology / Male / Medical prognosis / Metastases / Middle Aged / MPGM risk model / Mutation / mutation profiles / p53 Protein / Pathology / Patients / Platelet-derived growth factor / Platelet-derived growth factor receptors / Point mutation / Prediction models / Prognosis / Protein-tyrosine kinase / Proto-Oncogene Proteins p21(ras) / Receptors, LDL / Regression analysis / Retrospective Studies / Risk factors / Risk groups / RNA-Binding Proteins / Software / targeted sequencing / Tumor Suppressor Protein p53 / Tumors